



## **Annexon to Present at the BofA Securities 2021 Virtual Healthcare Conference**

May 5, 2021

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Today [Annexon, Inc.](#) ("Annexon") (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the Bank of America Securities 2021 Virtual Healthcare Conference on May 12, 2021 at 11:45 am EDT.

A live webcast of the event can be accessed under the 'Events & Presentations' section on the Investors page at [www.annexonbio.com](http://www.annexonbio.com). A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

### **About Annexon, Inc.**

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company's pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is deploying a disciplined, biomarker-driven development strategy designed to select indications, identify patients and measure target engagement and response to treatment. For more information, visit [www.annexonbio.com](http://www.annexonbio.com).

Investor Contacts: Jennifer Lew, Chief Financial Officer Annexon Biosciences [jlew@annexonbio.com](mailto:jlew@annexonbio.com) Sara Michelmore [smichelmore@macbiocom.com](mailto:smichelmore@macbiocom.com) Media Contact: Miriam Mason Annexon Biosciences [mmason@annexonbio.com](mailto:mmason@annexonbio.com)